The World Society of Paediatric Ophthalmology and Strabismus (WSPOS) released a consensus statement that formally recognized low-dose atropine eye drops as a safe, evidence-based, and effective intervention for slowing the progression of myopia in children, and is supporting approval of the drops in the United States. According to WSPOS, this position is supported by Level 1 evidence derived from multiple high-quality clinical trials that reinforce the role of low-dose atropine in myopia management.

WSPOS pointed out that commercially manufactured low-dose atropine eye drops are now available and utilized in many parts of the world, including in the United Kingdom, the European Union, Singapore, Japan, China, India, Hong Kong, Colombia, Chile, Peru, Mexico, Kenya (imported), and Australia. Additionally, these regions have established regulatory-approved production pathways that ensure predictable dosing, product stability, and safety, according to WSPOS.

However, North America along with much of Africa, remain without a regulatory-approved commercial formulation and continue to rely on compounded preparations, which are inherently more variable.

The WSPOS statement follows a similar statement of support from The American Academy of Orthokeratology and Myopia Control (AAOMC).